Rhythm Pharmaceuticals, Inc.'s SEC filings document a commercial-stage biopharmaceutical company whose disclosures center on IMCIVREE (setmelanotide), MC4R pathway rare-disease indications and related clinical and regulatory milestones. Recent Form 8-K reports include operating results, product-revenue commentary, FDA and European regulatory updates for acquired hypothalamic obesity, and trial disclosures for programs such as TRANSCEND and EMANATE.
Rhythm's proxy materials and governance filings disclose board composition, director elections, executive compensation, equity awards and shareholder voting matters. Other current reports record director changes, Regulation FD materials, presentations and press releases, tying corporate governance and public-company reporting to the company's rare neuroendocrine disease portfolio.
Rhythm Pharmaceuticals’ Chief Financial Officer Hunter C. Smith reported multiple open-market sales of common stock on February 10–12, 2026. These sales, executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025, left him holding 118,466 shares directly.
On February 11, 2026, Smith also received equity compensation in the form of 25,000 restricted stock units and stock options for 37,500 shares at an exercise price of $98.47. The RSUs vest in four equal annual installments from February 1, 2027 through February 1, 2030, while the options vest in 16 substantially equal quarterly installments after the grant date.
PRIMECAP Management Co. filed an amended Schedule 13G reporting its beneficial ownership of common stock of RYTM Pharmaceuticals, Inc. As of the event date, PRIMECAP reports beneficial ownership of 3,478,669 shares, representing 5.21% of the company’s outstanding class.
PRIMECAP has sole power to vote and dispose of all 3,478,669 shares, with no shared voting or dispositive power. The firm certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Rhythm Pharmaceuticals.
The Chief Financial Officer of a biopharmaceutical issuer filed a Form 4 showing open-market sales of common stock on February 4–5, 2026. On February 4, the officer sold 1,500 shares at a weighted average price of $104.7434, 1,000 shares at $106.604, and 747 shares at $107.6654. On February 5, the officer sold an additional 3,381 shares at $106.063.
After these transactions, the officer directly beneficially owned 125,537 shares of common stock. The filing notes that the sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025, and that each reported price is a weighted average for multiple trades within the stated price ranges.
A person filing on behalf of RYTM has submitted a Form 144 notice covering a planned sale of 18,406 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of February 5, 2026. The shares have an indicated aggregate market value of $1,987,295.82, compared with 66,736,056 shares of common stock outstanding. These shares were acquired as restricted stock units from the issuer on February 10, 2025. The form also notes a prior Rule 10b5-1 sale for Hunter Smith of 3,247 common shares on February 4, 2026, generating gross proceeds of $344,145.31.
A shareholder of RYTM filed a Form 144 notice to sell up to 3,247 shares of common stock through Morgan Stanley Smith Barney LLC on or about February 4, 2026 on NASDAQ. The filing shows an aggregate market value of $351,617.63 for these shares.
The shares to be sold were acquired from the issuer as restricted stock units on February 3, 2025, in the same amount of 3,247 shares. The table also lists 66,736,056 shares outstanding for this class of common stock.
EVP, Head of International Yann Mazabraud reported an equity award transaction involving restricted stock units and common stock of Pharmaceuticals, Inc. (ticker RYTM). On February 1, 2026, 5,500 restricted stock units were converted into 5,500 shares of common stock at $0 per share under transaction code M.
Following this transaction, Mazabraud directly beneficially owned 43,155 shares of common stock and 11,000 restricted stock units. Each restricted stock unit represents the right to receive one share of common stock, vesting in 25% increments on February 16, 2025, and February 1 of 2026, 2027, and 2028.
The Chief Financial Officer, Hunter C. Smith, reported equity compensation activity involving company stock on February 1, 2026. He converted 26,000 shares of common stock from restricted stock units, bringing his directly held common shares to 132,165 after the reported transactions.
To cover withholding taxes upon vesting, 10,750 common shares were withheld at a price of $108.99 per share, rather than being sold in the open market. The underlying restricted stock units convert into one share of common stock each and vest in four equal annual installments, with various grants vesting through February 2029. The restricted stock units have no expiration date.
Pharmaceuticals, Inc. Chief Technical Officer Joseph Shulman reported the vesting of 16,968 shares of common stock on February 1, 2026 from multiple restricted stock unit (RSU) awards. Each RSU converts into one share of common stock.
To satisfy withholding taxes on this vesting, 6,507 shares were withheld at $108.99 per share. After these transactions, Shulman directly beneficially owned 18,970 shares of common stock and continues to hold additional RSUs that vest in stages through 2029.
Rhythm Pharmaceuticals President and CEO David P. Meeker reported the vesting and conversion of restricted stock units into common stock on February 1, 2026. A total of 68,713 restricted stock units were exercised into common shares, and 31,522 shares were withheld at $108.99 per share to satisfy tax obligations. Following these transactions, Meeker directly holds 239,016 shares of common stock and 156,637 restricted stock units.
Pharmaceuticals, Inc.’s EVP and Head of North America, Jennifer Kayden Lee, reported routine equity activity on February 1, 2026. Restricted stock units converted into 22,612 shares of common stock, increasing her directly held stake before tax withholding.
To cover withholding taxes on the vesting, 9,237 common shares were withheld at $108.99 per share, leaving her with 19,233 shares of common stock held directly after the transactions. Several restricted stock unit awards continue to vest annually through dates ranging from February 1, 2027 to February 1, 2029, with remaining balances including 4,512, 11,000, and 27,487 restricted stock units.